Search clinical trials for: GSK2340274A

Total 26 results

GlaxoSmithKline

Completed

Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age

Influenza

Canada, United States
GlaxoSmithKline

Completed

Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older

Influenza

United States, Canada
GlaxoSmithKline

Completed

Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older

Influenza

United States, Canada
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults

Influenza

Belgium
GlaxoSmithKline

Completed

Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults

Influenza

United States, Canada
GlaxoSmithKline

Completed

Safety and Immune Response of Candidate H1N1 Influenza Vaccines GSK2340274A and GSK234072A in Children 3 to Less Than 10 Years Old

Influenza

Thailand, Philippines
GlaxoSmithKline

Completed

Study to Evaluate Immunological Equivalence Between Two Investigational Influenza Vaccines in Adults (H1N1)

Influenza

France, Germany
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults

Influenza

Belgium
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults

Influenza

Germany
GlaxoSmithKline

Completed

Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children Aged 10 to Less Than 18 Years

Influenza

Slovakia, Estonia
GlaxoSmithKline

Completed

Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of Age

Influenza

Thailand, Australia, Mexico, Costa Rica, Philippines, Colombia, Singapore, Brazil
GlaxoSmithKline

Completed

Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults

Influenza

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old

Influenza

United States
GlaxoSmithKline

Completed

Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1)

Influenza

Japan
GlaxoSmithKline

Withdrawn

Safety and Immune Response of One-Dose of Candidate H1N1 Influenza Vaccine GSK2340274A in Adults

Influenza
GlaxoSmithKline

Completed

Safety, Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)

Influenza

Spain
GlaxoSmithKline

Terminated

Study to Evaluate the Safety and Immunogenicity of GSK Biological Pandemic Candidate Influenza Vaccine (H1N1) in Children

Influenza

Czechia
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)

Influenza

Spain
GlaxoSmithKline

Completed

Study to Evaluate Immunogenicity & Safety of an Investigational Influenza Vaccine in Adults

Influenza

France
GlaxoSmithKline

Completed

Safety and Immunogenocity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Japanese Children

Influenza

Japan
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children

Influenza

Germany
GlaxoSmithKline

Completed

Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults

Influenza

Belgium
GlaxoSmithKline

Completed

Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)

Influenza

Germany
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults, Using Two Different Manufacturing Processes

Influenza

Germany
GlaxoSmithKline

Completed

Immunogenicity and Safety of Vaccine GSK2340272A (H1N1) and GSK Biologicals Fluarix™ Vaccine When Co-administered in Elderly

Influenza

Sweden
GlaxoSmithKline

Terminated

Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children

Influenza

Norway

3

Subscribe